Drug labels get supply chain transparency; customs gets a carve-out

What it does

This bill requires drug manufacturers to label finished drugs and active pharmaceutical ingredients with the name, location, and facility ID of the original manufacturer, plus supply chain information (packer/distributor). The information can appear on the label, package insert, or via QR code/barcode linking to an electronic portal. It also exempts drug products from separate customs country-of-origin marking if they comply with the new drug-labeling rule.

Why we flagged it

The bill's core function is to require disclosure of drug manufacturing and supply chain information on labels and via electronic portals. It is a transparency and traceability measure, not a subsidy, deregulation, or carve-out.

• Section 3 exempts drug products from customs country-of-origin marking (Tariff Act §304) if they comply with the new drug-labeling rule. This is substantively unrelated to drug labeling transparency and appears to reduce customs compliance burden for pharmaceutical importers.

What the text implies

• The 'original manufacturer' definition (last establishment conducting substantial manufacturing before interstate commerce) may create ambiguity for drugs manufactured through contract manufacturing or outsourced production, potentially allowing some supply chain steps to remain unlabeled.
• The electronic portal requirement creates a new compliance infrastructure; manufacturers must maintain searchable databases, which may impose ongoing IT and administrative costs that could be passed to consumers or insurers.
• Exemption from customs country-of-origin marking (Section 3) may reduce transparency at the border and could complicate enforcement of trade agreements or tariff classifications, though it simplifies labeling for importers.
• The 1-year implementation window is tight for manufacturers to redesign labels, update supply chain documentation, and build electronic portals, potentially creating short-term supply disruptions or labeling errors.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens gain transparency into drug sourcing and manufacturing, enabling informed decisions and helping identify counterfeit or contaminated products. The supply chain visibility supports public health oversight and reduces information asymmetry between consumers and manufacturers, with minimal direct cost to patients.

Who stands to gain

• software/IT vendors providing supply chain tracking and electronic portal solutions
• pharmaceutical manufacturers with transparent, domestic supply chains (competitive advantage over th
• contract manufacturers and logistics providers (increased demand for supply chain documentation and

Named in the bill

FDA (Food and Drug Administration), Federal Food, Drug, and Cosmetic Act, Tariff Act of 1930, pharmaceutical manufacturers, active pharmaceutical ingredient (API) suppliers, contract manufacturers, drug packers and distributors

Where it stands

2 cosponsors: 1 Democrats, 1 Republicans.

• Apr 14, 2026 — Introduced · Congress.gov: “Introduced in House”
• Apr 14, 2026 — Referred to House Committee on Energy and Commerce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 5 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $13,810,000 in lobbying spend. A filing names 53 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Rich McCormick, the sponsor, reported $478,500 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $7,360,000 on 1 filing
• American Hospital Association — $4,470,000 on 1 filing
• Gsk (fka Glaxosmithkline Inc.) — $890,000 on 1 filing
• Association for Accessible Medicines — $870,000 on 1 filing
• Professional Compounding Centers of America — $220,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.